PortalPublikationenLong-Term Follow-Up and Late Effects

Long-Term Follow-Up and Late Effects

Standard

Long-Term Follow-Up and Late Effects. / Hayden, Patrick; Gagelmann, Nico; Snowden, John.

The EBMT/EHA CAR-T Cell Handbook. Hrsg. / Nicolaus Kröger; John Gribben; Christian Chabannon; Ibrahim Yakoub-Agha; Hermann Einsele. 1. Aufl. Cham : Springer International Publishing, 2022. S. 183-187.

Publikationen: SCORING: Beitrag in Buch/Sammelwerk › Kapitel › Forschung

Harvard

Hayden, P, Gagelmann, N & Snowden, J 2022, Long-Term Follow-Up and Late Effects. in N Kröger, J Gribben, C Chabannon, I Yakoub-Agha & H Einsele (Hrsg.), The EBMT/EHA CAR-T Cell Handbook. 1 Aufl., Springer International Publishing, Cham, S. 183-187. https://doi.org/10.1007/978-3-030-94353-0_36

APA

Hayden, P., Gagelmann, N., & Snowden, J. (2022). Long-Term Follow-Up and Late Effects. in N. Kröger, J. Gribben, C. Chabannon, I. Yakoub-Agha, & H. Einsele (Hrsg.), The EBMT/EHA CAR-T Cell Handbook (1 Aufl., S. 183-187). Springer International Publishing. https://doi.org/10.1007/978-3-030-94353-0_36

Vancouver

Hayden P, Gagelmann N, Snowden J. Long-Term Follow-Up and Late Effects. in Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, Hrsg., The EBMT/EHA CAR-T Cell Handbook. 1 Aufl. Cham: Springer International Publishing. 2022. S. 183-187 https://doi.org/10.1007/978-3-030-94353-0_36

Bibtex

@inbook{4d20a867e4b4492d8f89978567471461,
title = "Long-Term Follow-Up and Late Effects",
abstract = "Little is known about the long-term effects of CAR-T cell therapy. Although medium-term complications, such as cytopenia and hypogammaglobulinaemia, may persist and require ongoing treatment, there do not appear to be other durable toxicities specific to this new immunotherapeutic class (Fried et al. 2019; Cordeiro et al. 2020; Cappell et al. 2020). However, to date, CAR-T therapy has been evaluated in patients with multiple relapsed diseases following several lines of treatment, including allogeneic stem cell transplantation, making it difficult to identify which effects may be directly attributable to this novel treatment. Nonetheless, as the use of CAR-T cell therapy increases, structured models for survivorship care will need to be established. The factors that will affect care requirements include the primary malignancy, prior treatment, the specific CAR-T therapy and patient age and frailty.",
author = "Patrick Hayden and Nico Gagelmann and John Snowden",
year = "2022",
doi = "10.1007/978-3-030-94353-0_36",
language = "English",
isbn = "978-3-030-94352-3",
pages = "183--187",
editor = "Nicolaus Kr{\"o}ger and John Gribben and Christian Chabannon and Ibrahim Yakoub-Agha and Hermann Einsele",
booktitle = "The EBMT/EHA CAR-T Cell Handbook",
publisher = "Springer International Publishing",
address = "Switzerland",
edition = "1",

}

RIS

TY - CHAP

T1 - Long-Term Follow-Up and Late Effects

AU - Hayden, Patrick

AU - Gagelmann, Nico

AU - Snowden, John

PY - 2022

Y1 - 2022

N2 - Little is known about the long-term effects of CAR-T cell therapy. Although medium-term complications, such as cytopenia and hypogammaglobulinaemia, may persist and require ongoing treatment, there do not appear to be other durable toxicities specific to this new immunotherapeutic class (Fried et al. 2019; Cordeiro et al. 2020; Cappell et al. 2020). However, to date, CAR-T therapy has been evaluated in patients with multiple relapsed diseases following several lines of treatment, including allogeneic stem cell transplantation, making it difficult to identify which effects may be directly attributable to this novel treatment. Nonetheless, as the use of CAR-T cell therapy increases, structured models for survivorship care will need to be established. The factors that will affect care requirements include the primary malignancy, prior treatment, the specific CAR-T therapy and patient age and frailty.

AB - Little is known about the long-term effects of CAR-T cell therapy. Although medium-term complications, such as cytopenia and hypogammaglobulinaemia, may persist and require ongoing treatment, there do not appear to be other durable toxicities specific to this new immunotherapeutic class (Fried et al. 2019; Cordeiro et al. 2020; Cappell et al. 2020). However, to date, CAR-T therapy has been evaluated in patients with multiple relapsed diseases following several lines of treatment, including allogeneic stem cell transplantation, making it difficult to identify which effects may be directly attributable to this novel treatment. Nonetheless, as the use of CAR-T cell therapy increases, structured models for survivorship care will need to be established. The factors that will affect care requirements include the primary malignancy, prior treatment, the specific CAR-T therapy and patient age and frailty.

U2 - 10.1007/978-3-030-94353-0_36

DO - 10.1007/978-3-030-94353-0_36

M3 - Chapter

SN - 978-3-030-94352-3

SP - 183

EP - 187

BT - The EBMT/EHA CAR-T Cell Handbook

A2 - Kröger, Nicolaus

A2 - Gribben, John

A2 - Chabannon, Christian

A2 - Yakoub-Agha, Ibrahim

A2 - Einsele, Hermann

PB - Springer International Publishing

CY - Cham

ER -